Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists

A compound of the formula (I)

• wherein
• Ar1 is monocyclic heteroaryl;
• Ar2 is bicyclic heteroaryl;
• R1 is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, nitro, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, cyano, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, C1-C4 alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(═O)—, HO(O═)C—, C1-C4 alkyl-O(O═)C—, R3N(R4)C(═O)—, C1-C4 alkylsulfonylamino, C3-C7 cycloalkyl, or R3C(═O)N(R4)—;
• R2 is hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, nitro, C1-C4 alkylsilyl, di(C1-C4 alkyl)silyl, tri(C1-C4 alkyl)silyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, cyano, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, C1-C4 alkylsulfonyl, aminosulfonyl, C1-C4 alkyl C(═O)—, HO(O═)C—, C1-C4 alkyl-O(O═)C—, R5N(R6)C(═O)—, C1-C4 alkylsulfonylamino, C3-C7 cycloalkyl, 3 to 7 membered heterocyclyl, or R5C(═O)N(R6)—;
• said C3-C7 cycloalkyl and 3 to 7 membered heterocyclyl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, cyano, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, R5N(R6)C(═O)— and nitro;
• X is independently selected from HO(O═)C—C0-C4alkyl, hydrogen, hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C7 cycloalkyl, cyano, alkylsulfonyl, C1-C4 alkyl C(═O)—, C1-C4 alkyl-O(O═)C—, and R7N(R8)C(═O)—;
• said alkyl may have independently 1 to 4 substituents independently selected from C1-C4 alkyl and halogen;
• m is 1, 2 or 3;
• when m is two or more than two, R1 may be same or different;
• n is 1, 2 or 3;
• when n is two or more than two, R2 may be same or different;
• p is 1, 2, 3, 4 or 5;
• when p is two or more than two, X may be same or different;
• R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, C1-C4 alkyl, hydroxy C1-C4 alkyl, C1-C4 alkoxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 alkylamino C1-C4 alkyl, di(C1-C4 alkyl)amino C1-C4 alkyl, 5 to 10 membered aryl, 5 to 10 membered aryl C0-C4 alkyl;
• said aryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkyl, amino C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C8 cycloalkyl, amino, C1-C4 alkylamino, di(C1-C4 alkyl)amino, C1-C4 alkylthio, and nitro;
• C3-C8 cycloalkyl, and 3 to 8 membered heterocyclyl C1-C4 alkyl;
• said heterocyclyl and alkyl may have independently 1 to 4 substituents independently selected from C1-C4 alkyl and halogen;
• or alternatively R3 and R4, R5 and R6 or R7 and R8 together with nitrogen atom to which they are attached may independently form a 4 to 8 membered ring which may contain nitrogen, oxygen or sulfur, wherein the 4 to 8 membered ring is optionally substituted with 1 to 6 substituents independently selected from the group consisting of hydroxy, C1-C4 alkyl, C1-C4 alkoxy, C3-C7 cycloalkyl, amino, oxo, C1-C4 alkylamino, and di(C1-C4 alkyl)amino;
• or a pharmaceutically acceptable salt thereof or a prodrug thereof.